A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies
Leukemia & Lymphoma | July 16, 2021 | Volume: 62 | Issue: 11 | Pages: 2625-2636
10.1080/10428194.2021.1938027
| PMID 34269152